Drugs / Fluphenazine
Fluphenazine
also known as
Anatensol · Dapotum · FLU · Flufenazina · Fluphenazine dihydrochloride · Fluphenazine hcl · FLUPHENAZINE HYDROCHLORIDE · Fluphenazini hydrochloridum · +6 more
Small molecule targets DRD2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | PERMITIL | — | 1959-09-09 | fda.gov ↗ |
Trials 5 · a red edge is where a trial was stopped
19581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00821301 | Dec 2008 → Aug 2010 | plasma cell myeloma | Immune Control | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00335647 | Jan 2006 → Apr 2008 | plasma cell myeloma | Immune Control | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT00161018 | Nov 2003 → Nov 2004 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02307396 | Feb 2015 → Jun 2016 | schizoaffective disorder, schizophrenia | Technical University of Munich | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02203786 Comparator | Sep 2009 → Jun 2015 | pathological gambling | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 2 | NCT00929578 Comparator | Nov 2008 → Nov 2010 | psoriasis | Tufts Medical Center | Completed | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluphenazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00929578 ↗ |
| Known as | Anatensol | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Dapotum | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | FLU | “The role of dopamine (DA) was assessed by pre-treating participants with the D2 receptor (D2R)-preferring antagonist, haloperidol (HAL; 3-mg) or mixed D1R-D2R antagonist,...” PMID 36919514 ↗ Mar 2023 |
| Known as | Flufenazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Fluphenazine dihydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Fluphenazine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | FLUPHENAZINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Fluphenazini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Moditen | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | NSC-179197 | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | NSC-62323 | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Permitil | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | Prolixin | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Known as | SQUIBB 4918 | ChEMBL registry synonym — accepted as the source's own label CHEMBL726 ↗ |
| Action | Inhibit | “mixed D1R-D2R antagonist, fluphenazine” PMID 36919514 ↗ Mar 20231“Dopamine D2 receptor antagonist” CHEMBL726 ↗ |
| Modality | Small molecule | — CHEMBL726 ↗ |
| Route | Intravenous | “Patients receive high-dose fluphenazine hydrochloride IV 3 times on day 1.” NCT00335647 ↗ |
| Target | DRD2 | “Dopamine D2 receptor antagonist” CHEMBL726 ↗ |